Polmacoxib: The review article provides extensive

The review article provides extensive overview on the promising pharmaceutical compound, polmacoxib also known as CG100649, explaining its pharmacological properties, chemical and physical properties, clinical studies and analytical methods. Polmacoxib is a novel nonsteroidal anti-inflammatory drug (NSAID) that has shown significant interest in recent years for its potential therapeutic benefits in Osteoarthritis treatment and distinct analytical characteristics. The chemical and ... Polmacoxib Polmacoxib is a first-in-class dual preferential Polmacoxib is the first, tissue-selective and once-a-day COX2/carbonic anhydrase I/II inhibitor. osteoarthritis drug with a novel mode of action that It is approved for osteoarthritis treatment in South Korea & specifically targets affected joints to relieve pain and restore Turkey and ... Polmacoxib is a NSAID used to treat osteoarthritis that inhibits COX-2 and carbonic anhydrase. It was approved in South Korea in 2015 and has a similar cardiovascular risk profile to celecoxib. The review article provides extensive overview on the promising pharmaceutical compound, polmacoxib also known as CG100649, explaining its pharmacological properties, chemical and physical ...